Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells

Experimental Dermatology

Volumn 24, Issue 1, 2016, Pages 35-41

  Nieda, Mie ^a   Terunuma, Hiroshi ^a,b,c   Eiraku, Yuuta ^a   Deng, Xuewen ^a   Nicol, Andrew J ^d  

^a Biotherapy Institute of Japan   (Japan)

^b Tokyo Clinic   (Japan)

^c Southern Tohoku General Hospital   (Japan)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

IFN ; Immunotherapy; Melanoma antigen specific CD8+ T; V 9 T; Zoledronate

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD56 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MELANOMA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; T-CELL RECEPTOR VGAMMA9, HUMAN;

ADHERENT CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTATIC MELANOMA; MONOCYTE; PSEUDOPODIUM; T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; MELANOMA; METABOLISM; MONONUCLEAR CELL; PHENOTYPE; SKIN NEOPLASMS;

ANTIGENS, CD14; ANTIGENS, CD56; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DIPHOSPHONATES; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MELANOMA; MONOCYTES; PEPTIDES; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SKIN NEOPLASMS;

EID: 84920616066     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12581     Document Type: Article

References (39)

1. Figdor C G, de Vries I J, Lesterhuis W J et al. Nat Med 2004: 10: 475-480.
2. Fong L, Engleman E G. Annu Rev Immunol 2000: 18: 245-273.
3. Nestle F O. Oncogene 2000: 19: 6673-6679.
4. Sallusto F, Lanzavecchia A. J Exp Med 1994: 179: 1109-1118.
5. Nestle F O, Alijagic S, Gilliet M et al. Nat Med 1998: 4: 328-332.
6. Paquette R L, Hsu N C, Kiertscher S M et al. J Leukoc Biol 1998: 64: 358-367.
7. Farkas A, Kemeny L. Br J Dermatol 2011: 165: 247-254.
8. Santini S M, Lepenta C, Santodonato L et al. Dendritic Cells, Handbook of Experimental Pharmacology. Lombardi G, Riffo-Vasquez Y. (eds.), Berlin, Heiderberg: Springer-Verlag, 2009: 188: 295-317.
9. Papewalis C, Jacobs B, Wuttke M et al. J Immunol 2008: 180: 1462-1470.
10. Gruenbacher G, Gander H, Rahm A et al. Blood 2009: 114: 4422-4431.
11. Lanier L L, Chang C, Azuma M et al. J Immunol 1991: 146: 4421-4426.
12. Pittet M J, Speiser D E, Valmori D et al. J Immunol 2000: 64: 1148-1152.
13. Alexander A A, Maniar A, Cummings J S et al. Clin Cancer Res 2008: 14: 4232-4240.
14. Urban E M, Li H, Armstrong C et al. BMC Immunol 2009: 10: 50.
15. Cohavy O, Targan S R. J Immunol 2007: 178: 5524-5532.
16. Orsini G, Failli A, Legitimo A et al. Exp Biol Med 2011: 236: 1420-1426.
17. Takahara M, Miyai M, Tomiyama M et al. J Leukoc Biol 2008: 83: 742-754.
18. Castella B, Riganti C, Fiore F et al. J Immunol 2011: 187: 1578-1590.
19. Valmori D, Pittet M J, Rimoldi D et al. Cancer Res 1999: 59: 2167-2173.
20. Sasawatari S, Tadaki T, Isogai M et al. Immunol Cell Biol 2006: 84: 512-521.
21. Albert M L, Pearce S F, Francisco L M et al. J Exp Med 1998: 188: 1359-1368.
22. Verdegaal E M, Visser M, Ramwadoebe T H et al. Cancer Immunol Immunjournal 2011: 60: 953-963.
23. Payne M J, Argyropoulou K, Lorigan P et al. J Clin Oncol 2014: 32: 185-190.
24. Wang W, Edington H D, Rao U N et al. J Invest Dermatol 2008: 128: 1997-2002.
25. Odigie M, Osinusi A, Barrett L et al. AIDS Res Hum Retroviruses 2014: 30: 775-782.
26. Li Z, Zhang Y, An J et al. J Clin Virol 2014: 60: 190-195.
27. Zahn S, Graef M, Patsinakidis N et al. Exp Dermatol 2014: 23: 516-518.
28. Ghoreishi M, Vera Kellet C, Dutz J P. Exp Dermatol 2012: 21: 417-419.
29. Pfeffer L M, Dinarello C A, Herberman R B et al. Cancer Res 1998: 58: 2489-2499.
30. Marrack P, Kappler J, Mitchell T. J Exp Med 1999: 189: 521-530.
31. Hillyer P, Raviv N, Gold D M et al. Eur J Immunol 2013: 43: 3197-3208.
32. Kolumam G A, Thomas S, Thompson L J et al. J Exp Med 2005: 202: 637-650.
33. Lim J Y, Gerber S A, Murphy S P et al. Cancer Immunol Immunjournal 2014: 63: 257-271.
34. Markova A A, Mihm U, Schlaphoff V et al. PLoS ONE 2014: 9: e94512.
35. Lunemann S, Malone D F, Grabowski J et al. Gut. 2014 Apr. doi: 10.1136/gutjnl-2014-306767 [Epub ahead of print]
36. Tosi D, Valenti R, Cova A et al. J Immunol 2004: 172: 5363-5370.
37. Groh V, Rhinehart R, Secrist H et al. Proc Natl Acad Sci USA 1999: 96: 5879-6884.
38. Spadaro F, Lapenta C, Donati S et al. Blood 2012: 119: 1407-1417.
39. Mohty M, Vialle-Castellano A, Nunes J A et al. J Immunol 2003: 171: 3385-3393.